The latest update is out from Merus (MRUS).
Merus N.V. has appointed Fabian Zohren, previously with Immunogen and Pfizer, as their new Chief Medical Officer, starting July 1, 2024, with a substantial salary and bonus structure, and stock option incentives that vest over four years. Additionally, the company has arranged separation agreements with outgoing executives, Hui Liu and Andrew Joe, providing severance benefits and extended option exercise periods, and has engaged Dr. Joe as a consultant for three months post-termination. This strategic move could signal a new direction for the company, potentially impacting Merus N.V.’s future growth and stock performance.
Find detailed analytics on MRUS stock on TipRanks’ Stock Analysis page.
